Found: 4
Select item for more details and to access through your institution.
Talazoparib in Patients with a Germline BRCA‐Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial.
- Published in:
- Oncologist, 2020, v. 25, n. 3, p. e439, doi. 10.1634/theoncologist.2019-0493
- By:
- Publication type:
- Article
Talazoparib Exposure‐Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial.
- Published in:
- Journal of Clinical Pharmacology, 2020, v. 60, n. 10, p. 1324, doi. 10.1002/jcph.1623
- By:
- Publication type:
- Article
Exposure‐Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials.
- Published in:
- Journal of Clinical Pharmacology, 2020, v. 60, n. 10, p. 1334, doi. 10.1002/jcph.1626
- By:
- Publication type:
- Article
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy.
- Published in:
- JNCI Cancer Spectrum, 2020, v. 4, n. 1, p. N.PAG, doi. 10.1093/jncics/pkz085
- By:
- Publication type:
- Article